-+ 0.00%
-+ 0.00%
-+ 0.00%

Agomab Therapeutics Director David R. Epstein Reports Acquisition of $88,679.20 in Common Shares

PUBT·11/16/2026 11:46:09
Diffusion vocale
Agomab Therapeutics Director David R. Epstein Reports Acquisition of $88,679.20 in Common Shares
  • Agomab Therapeutics director David R. Epstein purchased 14,980 common shares at prices ranging from $5.75 to $6.02 per share.
  • His direct beneficial ownership rose to 54,980 common shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001445826-26-000019), on November 16, 2026, and is solely responsible for the information contained therein.